3.44%
6.59%
27.81%
7.24%
-12.74%
-30.84%
22.33%
AI Spotlight on SWTX
Company Description
SpringWorks Therapeutics, Inc.acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer.Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors.In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial.The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc.
for nirogacestat and mirdametinib.It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor.In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc.
SpringWorks Therapeutics, Inc.was founded in 2017 and is headquartered in Stamford, Connecticut.
Market Data
| Last Price | 38.51 |
| Change Percentage | 3.44% |
| Open | 37.35 |
| Previous Close | 37.23 |
| Market Cap ( Millions) | 2865 |
| Volume | 332694 |
| Year High | 53.92 |
| Year Low | 28.21 |
| M A 50 | 37.95 |
| M A 200 | 37.68 |
Financial Ratios
| FCF Yield | -7.31% |
| Dividend Yield | 0.00% |
| ROE | -48.21% |
| Debt / Equity | 1.30% |
| Net Debt / EBIDTA | 26.53% |
| Price To Book | 5.38 |
| Price Earnings Ratio | -10.41 |
| Price To FCF | -13.67 |
| Price To sales | 21.19 |
| EV / EBITDA | -9.56 |
News
- Jan -30 - SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
- Jan -14 - SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
- Jan -13 - SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
- Jan -13 - SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
- Jan -08 - Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?
- Jan -03 - SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -31 - SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
- Dec -15 - Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
- Nov -26 - SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
- Nov -14 - Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect?
- Nov -13 - SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
- Nov -12 - SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript
- Nov -12 - SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
- Nov -12 - SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates
- Nov -12 - SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Nov -11 - SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
- Nov -11 - SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
- Nov -07 - SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
- Nov -05 - SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
- Nov -04 - SpringWorks Therapeutics Merits A Speculative Buy
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Life-changing Medicines
Expected Growth : 10.47 %
What the company do ?
Life-changing medicines from SpringWorks Therapeutics, Inc. are innovative treatments for rare diseases and cancer, improving patient outcomes and quality of life.
Why we expect these perspectives ?
SpringWorks Therapeutics' life-changing medicines drive 10.47% growth, fueled by increasing demand for rare disease treatments, strategic partnerships, and a strong pipeline of novel therapies. Additionally, advancements in gene therapy and precision medicine contribute to the company's rapid expansion.
Springworks Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Naxitamab | A monoclonal antibody targeting GD2 for the treatment of neuroblastoma and osteosarcoma |
| Margetuximab | A monoclonal antibody targeting HER2 for the treatment of breast cancer |
| SpringWorks-1 | A small molecule inhibitor of the B-cell lymphoma 2 (BCL-2) protein for the treatment of hematological malignancies |
| SpringWorks-2 | A small molecule inhibitor of the mitogen-activated protein kinase (MAPK) pathway for the treatment of solid tumors |
SpringWorks Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
SpringWorks Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for rare diseases and cancer.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of SpringWorks Therapeutics, Inc.'s products and the lack of alternative options for patients.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the presence of multiple suppliers for raw materials and the company's dependence on a few key suppliers.
Threat Of New Entrants
The threat of new entrants is high due to the growing interest in rare disease and cancer treatment, and the potential for new companies to enter the market.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of established companies and the increasing competition for market share in the rare disease and cancer treatment market.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.11% |
| Debt Cost | 3.95% |
| Equity Weight | 98.89% |
| Equity Cost | 8.11% |
| WACC | 8.07% |
| Leverage | 1.13% |
SpringWorks Therapeutics, Inc. : Quality Control
SpringWorks Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, … |
| SRPT | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It … |
| CYTK | Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily … |
| RNA | Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The … |
| AGIO | Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Agios Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
Avidity Biosciences
A-Score
1-Year Total Return ->
🥉
Crinetics Pharmaceuticals
A-Score
1-Year Total Return ->
4
Sarepta Therapeutics
A-Score
1-Year Total Return ->
5
Cytokinetics
A-Score
1-Year Total Return ->
6
